The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease
Background: Approximately 10–20 % of individuals develop a recrudescent or persistent fever after intravenous immunoglobulin (IVIG) infusion for the initial treatment of Kawasaki disease. The aim of this study was to evaluate the efficacy and safety of the initial IVIG treatment of Kawasaki disease...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Pediatrics and Neonatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957224000032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241020261826560 |
|---|---|
| author | Satoshi Asano Naoya Fukushima Kenichiro Yamada |
| author_facet | Satoshi Asano Naoya Fukushima Kenichiro Yamada |
| author_sort | Satoshi Asano |
| collection | DOAJ |
| description | Background: Approximately 10–20 % of individuals develop a recrudescent or persistent fever after intravenous immunoglobulin (IVIG) infusion for the initial treatment of Kawasaki disease. The aim of this study was to evaluate the efficacy and safety of the initial IVIG treatment of Kawasaki disease based on duration of infusion. Methods: This retrospective, single-center study included 53 patients with Kawasaki disease who were initially treated with 2 g/kg of IVIG by means of a single infusion from June 2018 to August 2019. We classified patients into two groups based on the duration of the infusion: the 12-h group and the 24-h group. We compared the treatment response of the primary IVIG and its adverse events using the Mann-Whitney U test and Fisher's exact or Chi-square tests. Results: There were no significant differences in the response to initial IVIG treatment between the two groups. The duration from treatment onset to defervescence was shorter in the 12-h group than the 24-h group (7 h vs. 12 h, respectively, p = 0.07); however, this was not significant. There were no significant between-group differences regarding adverse events. Conclusion: We concluded that the initial 12-h IVIG treatment was comparable to the 24-h treatment in terms of efficacy and safety. This will enable physicians to feel confident about pursuing a shorter course of treatment with similar results as conventional treatment and decide on administering additional therapy to their patients. |
| format | Article |
| id | doaj-art-9efbbddcefbe4118ac707a27cdb1b483 |
| institution | OA Journals |
| issn | 1875-9572 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pediatrics and Neonatology |
| spelling | doaj-art-9efbbddcefbe4118ac707a27cdb1b4832025-08-20T02:00:42ZengElsevierPediatrics and Neonatology1875-95722024-09-0165544144410.1016/j.pedneo.2023.09.012The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki diseaseSatoshi Asano0Naoya Fukushima1Kenichiro Yamada2Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa-ken, JapanCorresponding author.; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa-ken, JapanDepartment of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa-ken, JapanBackground: Approximately 10–20 % of individuals develop a recrudescent or persistent fever after intravenous immunoglobulin (IVIG) infusion for the initial treatment of Kawasaki disease. The aim of this study was to evaluate the efficacy and safety of the initial IVIG treatment of Kawasaki disease based on duration of infusion. Methods: This retrospective, single-center study included 53 patients with Kawasaki disease who were initially treated with 2 g/kg of IVIG by means of a single infusion from June 2018 to August 2019. We classified patients into two groups based on the duration of the infusion: the 12-h group and the 24-h group. We compared the treatment response of the primary IVIG and its adverse events using the Mann-Whitney U test and Fisher's exact or Chi-square tests. Results: There were no significant differences in the response to initial IVIG treatment between the two groups. The duration from treatment onset to defervescence was shorter in the 12-h group than the 24-h group (7 h vs. 12 h, respectively, p = 0.07); however, this was not significant. There were no significant between-group differences regarding adverse events. Conclusion: We concluded that the initial 12-h IVIG treatment was comparable to the 24-h treatment in terms of efficacy and safety. This will enable physicians to feel confident about pursuing a shorter course of treatment with similar results as conventional treatment and decide on administering additional therapy to their patients.http://www.sciencedirect.com/science/article/pii/S1875957224000032Coronary artery abnormalitiesInfusion durationIntravenous immunoglobulinIVIG safetyKawasaki disease |
| spellingShingle | Satoshi Asano Naoya Fukushima Kenichiro Yamada The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease Pediatrics and Neonatology Coronary artery abnormalities Infusion duration Intravenous immunoglobulin IVIG safety Kawasaki disease |
| title | The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease |
| title_full | The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease |
| title_fullStr | The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease |
| title_full_unstemmed | The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease |
| title_short | The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease |
| title_sort | efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of kawasaki disease |
| topic | Coronary artery abnormalities Infusion duration Intravenous immunoglobulin IVIG safety Kawasaki disease |
| url | http://www.sciencedirect.com/science/article/pii/S1875957224000032 |
| work_keys_str_mv | AT satoshiasano theefficacyandsafetyofintravenousimmunoglobulininfusionin12hfortheinitialtreatmentofkawasakidisease AT naoyafukushima theefficacyandsafetyofintravenousimmunoglobulininfusionin12hfortheinitialtreatmentofkawasakidisease AT kenichiroyamada theefficacyandsafetyofintravenousimmunoglobulininfusionin12hfortheinitialtreatmentofkawasakidisease AT satoshiasano efficacyandsafetyofintravenousimmunoglobulininfusionin12hfortheinitialtreatmentofkawasakidisease AT naoyafukushima efficacyandsafetyofintravenousimmunoglobulininfusionin12hfortheinitialtreatmentofkawasakidisease AT kenichiroyamada efficacyandsafetyofintravenousimmunoglobulininfusionin12hfortheinitialtreatmentofkawasakidisease |